...
首页> 外文期刊>BMC Microbiology >A newly identified linear epitope on non-RBD region of SARS-CoV-2 spike protein improves the serological detection rate of COVID-19 patients
【24h】

A newly identified linear epitope on non-RBD region of SARS-CoV-2 spike protein improves the serological detection rate of COVID-19 patients

机译:SARS-COV-2穗蛋白的非RBD区域的新鉴定的线性表位提高了Covid-19患者的血清学检测率

获取原文
           

摘要

Serological test is helpful in confirming and tracking infectious diseases in large population with the advantage of fast and convenience. Using the specific epitope peptides identified from the whole antigen as the detection antigen is sensitive and relatively economical. The development of epitope peptide-based detection kits for COVID-19 patients requires comprehensive information about epitope peptides. But the data on B cell epitope of SARS-CoV-2 spike protein is still limited. More importantly, there is a lack of serological data on the peptides in the population. In this study, we aimed to identify the B cell epitope peptides of spike protein and detect the reactivity in serum samples, for further providing data support for their subsequent serological applications. Two B cell linear epitopes, P104 and P82, located in non-RBD region of SARS-CoV-2?S protein were identified by indirect ELISA screening of an overlapping peptide library of the S protein with COVID-19 patients’ convalescent serum. And the peptides were verified by testing with 165 serum samples. P104 has not been reported previously; P82 is contained in peptide S21P2 reported before. The positive reaction rates of epitope peptides S14P5 and S21P2, the two non-RBD region epitopes identified by Poh et al., and P82 and P104 were 77.0%, 73.9%, 61.2% and 30.3%, respectively, for 165 convalescent sera, including 30 asymptomatic patients. Although P104 had the lowest positive rate for total patients (30.3%), it exhibited slight advantage for detection of asymptomatic infections (36.7%). Combination of epitopes significantly improved the positive reaction rate. Among all combination patterns, (S14P5?+?S21P2?+?P104) pattern exhibited the highest positive reaction rate for all patients (92.7%), as well as for asymptomatic infections (86.7%), confirming the feasibility of P104 as supplementary antigen for serological detection. In addition, we analyzed the correlation between epitopes with neutralizing antibody, but only S14P5 had a medium positive correlation with neutralizing antibody titre (rs?=?0.510, P??0.01). Our research proved that epitopes on non-RBD region are of value in serological detection especially when combination more than one epitope, thus providing serological reaction information about the four epitopes, which has valuable references for their usage.
机译:血清学检测有助于确认和跟踪大群中的传染病,以快速和便利的优势。使用从整个抗原鉴定的特定表位肽作为检测抗原是敏感的且相对经济的。 Covid-19患者基于表位肽的检测试剂盒的发展需要有关表位肽的全面信息。但SARS-COV-2穗蛋白的B细胞表位的数据仍然有限。更重要的是,群体中缺乏血清学数据。在该研究中,我们旨在鉴定穗蛋白的B细胞表位肽,并检测血清样品中的反应性,以进一步为其随后的血清学应用提供数据支持。通过间接ELISA筛选SARS-COV-2βS蛋白的非RBD区域的两种B细胞线性表位,P104和P82鉴定了CoVID-19患者康复血清的蛋白质的重叠肽库。通过用165个血清样品测试验证肽。 P104之前尚未报告; P82含有以前报道的肽S21P2。表位肽S14P5和S21P2的正反应速率,POH等人鉴定的两个非RBD区表位,分别为77.0%,73.9%,61.2%和30.3%,适用于165次促进血清,包括30例无症状患者。虽然P104对总患者的阳性率最低(30.3%),但它表现出对无症状感染的略有优势(36.7%)。表位的组合显着提高了阳性反应速率。在所有组合模式中,(S14P5?+ΔS21P2?+ΔP104)模式表现出所有患者的最高反应速率(92.7%),以及无症状感染(86.7%),证实P104作为补充抗原的可行性用于血清学检测。此外,我们分析了表位与中和抗体的相关性,但只有S14P5与中和抗体滴度的培养基正相关(Rs?= 0.510,p≤0.01)。我们的研究证明,非RBD地区的表位在血清学检测中具有价值,特别是当组合多于一个表位时,从而提供有关四个表位的血清学反应信息,这对其使用有价值的参考。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号